Bio-Path Holdings Announces First Patient Dosed in Phase I/Ib Study of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients

Bio-Path Holdings, Inc. announced the enrollment and dosing of the first patient in a Phase I/Ib clinical trial evaluating the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia patients.